BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Ruler MAP, Peters FP, Slingerland M, Fiocco M, Grootenboers DARH, Vulink AJE, Marijnen CAM, Neelis KJ. Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Diseases of the Esophagus 2017;30:1-9. [DOI: 10.1093/dote/dow033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang SX, Marshall MB. Chemoradiation Therapy as Definitive Treatment of Esophageal Cancer. Surg Clin North Am 2021;101:443-51. [PMID: 34048764 DOI: 10.1016/j.suc.2021.03.006] [Reference Citation Analysis]
2 Owens R, Cox C, Gomberg S, Pan S, Radhakrishna G, Parikh S, Goody R, Hingorani M, Prince S, Bird T, Dorey N, Macgregor U, Al-Chamali H, Hurt C, Mukherjee S. Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clin Oncol (R Coll Radiol) 2020;32:121-30. [PMID: 31662220 DOI: 10.1016/j.clon.2019.09.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Liu Q, Xia Y, Chen Y, Zhang J, Deng J, Zhao K. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol 2020;15:75. [PMID: 32268925 DOI: 10.1186/s13014-020-01518-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Xia Y, Li YH, Chen Y, Liu Q, Zhang JH, Deng JY, Ai TS, Zhu HT, Badakhshi H, Zhao KL. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma. Int J Clin Oncol 2018;23:458-65. [PMID: 29435872 DOI: 10.1007/s10147-018-1240-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Walterbos NR, Fiocco M, Neelis KJ, van der Linden YM, Langers AMJ, Slingerland M, de Steur WO, Peters FP, Lips IM. Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer. Clin Transl Radiat Oncol 2019;17:24-31. [PMID: 31193091 DOI: 10.1016/j.ctro.2019.04.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 van Holstein Y, Trompet S, van Deudekom FJ, van Munster B, de Glas NA, van den Bos F, Uit den Boogaard A, van der Elst MJT, van der Kaaij MAE, Neelis KJ, Langers AMJ, Slingerland M, Portielje JEA, Mooijaart SP. Geriatric assessment and treatment outcomes in a Dutch cohort of older patients with potentially curable esophageal cancer. Acta Oncol 2022;:1-9. [PMID: 35193449 DOI: 10.1080/0284186X.2022.2036366] [Reference Citation Analysis]
7 Mei LX, Mo JX, Chen Y, Dai L, Wang YY, Chen MW. Esophagectomy versus definitive chemoradiotherapy as initial treatment for clinical stage I esophageal cancer: a systematic review and meta-analysis. Dis Esophagus 2021:doab049. [PMID: 34318324 DOI: 10.1093/dote/doab049] [Reference Citation Analysis]
8 Kosovec JE, Zaidi AH, Omstead AN, Matsui D, Biedka MJ, Cox EJ, Campbell PT, Biederman RWW, Kelly RJ, Jobe BA. CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease. Oncotarget 2017;8:100421-32. [PMID: 29245989 DOI: 10.18632/oncotarget.22244] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]